These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Letter: Treatment of systemic lupus erythematosus with levamisole. Kassan SS Ann Allergy; 1976 Aug; 37(2):148-50. PubMed ID: 970682 [No Abstract] [Full Text] [Related]
23. [The importance of immunofluorescence examinations in the diagnosis of lupus erythematosus (author's transl)]. Gligora M Lijec Vjesn; 1977 Apr; 99(4):250-4. PubMed ID: 329027 [No Abstract] [Full Text] [Related]
24. [Study of circulating immunoblasts in the peripheral blood of patients with systemic lupus erythematosus and other rheumatic diseases]. Bulanova TD; le Go A; Alekberova ZS; Polianskaia IP Ter Arkh; 1980; 52(6):64-7. PubMed ID: 6967635 [No Abstract] [Full Text] [Related]
29. [Clinical cases and laboratory data in a group of mesenchymopathies: lupus erythematosus, dermatomyositis, scleroderma]. Meneghini CL; Bonifazi E J Med Lyon; 1972 Sep; 53(232):1123-31. PubMed ID: 4539165 [No Abstract] [Full Text] [Related]
31. [Complement fixation test with collagen antigen in patients with different forms of lupus erythematosus]. Lomkin AN; Zisel'son AD; Zubzhitskiĭ IuN Vestn Dermatol Venerol; 1967 Nov; 41(11):38-42. PubMed ID: 5621354 [No Abstract] [Full Text] [Related]
32. [Clinical aspects of chronic lupus erythematosus in a markedly continental climate]. Grebennikov VA; Gavrilenko VE Vestn Dermatol Venerol; 1984 May; (5):20-4. PubMed ID: 6234716 [No Abstract] [Full Text] [Related]
33. [Immunosuppression of burn patients. Treatment with levamisole]. Renoux G; Renoux M; Greco JM Ann Chir Plast; 1979; 24(1):57-9. PubMed ID: 317422 [No Abstract] [Full Text] [Related]
35. [Soluble interleukin 2 receptor as activity parameter in serum of systemic and discoid lupus erythematosus]. Blum C; Zillikens D; Tony HP; Hartmann AA; Burg G Hautarzt; 1993 May; 44(5):290-5. PubMed ID: 8320115 [TBL] [Abstract][Full Text] [Related]
36. [Pathogenesis, diagnosis and therapy of transitional (presystemic) forms of lupus erythematosus]. Shaposhnikov OK; Gorbunov VF Vestn Dermatol Venerol; 1981 Nov; (11):4-7. PubMed ID: 6976049 [No Abstract] [Full Text] [Related]
37. Effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus. Bonomini V; Vangelista A; Frascà GM; Nanni-Costa A; Borgnino LC Clin Nephrol; 1984 Sep; 22(3):121-6. PubMed ID: 6237815 [TBL] [Abstract][Full Text] [Related]
38. [Lysozyme in the combined therapy of erythematosis]. Glavinskaia TA; Pavlova LT; Dorofeĭchuk VG Vestn Dermatol Venerol; 1990; (3):21-5. PubMed ID: 2368487 [TBL] [Abstract][Full Text] [Related]
39. The immunofluorescent "band" test for lupus erythematosus. I. Morphologic variations of the band of localized immunoglobulins at the dermal-epidermal junction in lupus erythematosus. Burnham TK; Fine G Arch Dermatol; 1969 Apr; 99(4):413-20. PubMed ID: 4181409 [No Abstract] [Full Text] [Related]
40. [Clinical picture and course of chronic lupus erythematosus between 1959 and 1969]. Mieczyńska-Wójcik Z Przegl Dermatol; 1971; 58(5):587-93. PubMed ID: 5139058 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]